18 / 19
Page 46
allied
academies
Asian Journal of Biomedical and Pharmaceutical Sciences | Volume 8
May 14-15, 2018 | Montreal, Canada
Global Summit on
Biopharma & Biotherapeutics
B
iopharmaceutical medicines represent a growing share
of the global pharmaceutical market, and with many of
these biopharmaceutical products facing loss of exclusivity
rights, also biosimilars may now enter the biopharmaceutical
market. Totaling US$ 228 billion in global sales in 2016
(Troein, 2017), biopharmaceutical medicines represent a
growing share of the global pharmaceutical market. With
many of these biopharmaceutical products facing loss of
patent protection and other exclusivity rights, also non-
innovator versions of these molecules, biosimilars, may
now enter the market, resulting in a shift of market shares
(IMS Health, 2016), revision of strategies of companies and
attraction of new players to the biopharmaceutical market.
Due to lower research and development costs and increase
in competition, biosimilars offer a lower cost alternative
to expensive biopharmaceutical therapies. By adopting
biosimilars, health care systems can expand patient access,
offer more treatment options to physicians and have a
new tool to control increasing health care expenses (IMS
Institute for Healthcare Informatics, 2016). Overall, large
investments have been made by companies to compete on
the biopharmaceutical market.
e:
ryousif@amicogroup.comBiopharmaceutical companies and market analysis
Robert Yousif
Alcon Vision Care, Kuwait